# Sutro Biopharma

基于 E. coli/CHO 裂解物的 XpressCF® 平台——抗体和 ADC，反应器达数千升。

Source: https://cn.bioecon.ru/companies/sutro-biopharma/
Updated: 2026-06-24

- 国家: United States

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 成立 | 2003年 | https://ir.sutrobio.com/financials/sec-filings/content/0001193125-26-119873/stro-20251231.htm, https://www.sutrobio.com/wp-content/uploads/2020/09/World-ADC-Shabbir-Anik-Sutro-FINAL-compressed.pdf |
| 员工人数 | 134(截至2026年3月) | https://www.sec.gov/Archives/edgar/data/1382101/000119312526224170/R11.htm |
| 总部 | 加利福尼亚州南旧金山（South San Francisco） | https://ir.sutrobio.com/financials/sec-filings/content/0001193125-26-119873/stro-20251231.htm, https://www.sutrobio.com/wp-content/uploads/2020/09/World-ADC-Shabbir-Anik-Sutro-FINAL-compressed.pdf |
| 生产基地 | 加利福尼亚州圣卡洛斯（运营已停止，预计2026年退出） | https://www.pharmamanufacturing.com/all-articles/article/55277392/sutro-to-exit-internal-gmp-manufacturing-facility-by-end-of-2025-as-part-of-restructuring |
| 产能 | 商业规模生产由外部CMO完成，例如在勃林格殷格翰工厂进行的4,500升批次生产 | https://www.pharmamanufacturing.com/all-articles/article/55277392/sutro-to-exit-internal-gmp-manufacturing-facility-by-end-of-2025-as-part-of-restructuring, https://www.sutrobio.com/sutro-biopharma-and-boehringer-ingelheim-bioxcellence-collaboration-established-first-in-class-cell-free-capabilities-at-commercial-scale/ |

独立来源: ir.sutrobio.com, pharmamanufacturing.com, sec.gov

## 技术

- [无细胞系统与无细胞生物制造](https://cn.bioecon.ru/technology/cell-free-systems-cell-free-bioproduction/)